The 72nd Annual Scientific Meeting of the American Academy of Forensic Sciences (AAFS) will be held February 17-22, 2020, in Anaheim, California.

The Program Committee solicits the submission of abstracts on topics of interest to the forensic science community. August 1, 2019, is the deadline for the submission of abstracts.

Scientific papers selected for presentation will be divided into two groups:

- Platform Presentation (standard scientific session)
- Poster Session

The Program Committee will select appropriate abstracts from those submitted by the August 1, 2019, deadline.

Abstracts of papers must be submitted on the official abstract form. Specific format and content requirements for the abstracts are noted on the form. A current copy of the presenting author’s curriculum vitae must be attached to the original abstract form.

To submit your abstract online, go to the AAFS website at: www.aafs.org.

Notification of Acceptance

Notification of Acceptance will be mailed to all presenting authors by November 15, 2019. Meeting registration materials will be sent to presenting authors.

Oral Presentations

Time

The final determination as to the length of time that will be allocated to a specific paper rests with the Section Program Chair. However, 15-minute presentations are standard.

Poster Presentations

Preparation

Authors have complete freedom to choose ways of displaying their information in figures, tables, text, photographs, etc. However, they should avoid crowding too much information into a limited space. The poster may be augmented by the use of manuscripts and sketch pads with marking pens.

Abstract Length

A single-spaced, one-page length document containing a minimum of 400 words to a maximum of 700 words is required. Please attach additional sheet(s) if needed.

Key Words

Each author is to provide three key words or terms in the space provided on the abstract form.

General Information cont.

Oral Presentation

Each scientific session meeting room will be equipped with a lighted pointer, lectern, microphone, LCD projector, and screen. Requests for additional audio-visual equipment will be reviewed by the Program Committee and are subject to approval by the Section Chair.

Poster Presentation

Each author selected for poster presentation will be provided with a 4’ x 8’ tack board on which to display material related to his/her presentation. Thumb tacks will be provided.

Meeting Registration

All speakers and presenters (oral or poster) are required to register for the annual meeting. If your abstract is accepted for presentation, you will be required to pay the basic registration fee for the annual meeting.

Commercial & Conflict of Interest

Commercial Interest

Commercial Interests are any proprietary entity producing goods or services, as well as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. Providers of clinical service directly to patients are not considered commercial interests.

Conflict of Interest

Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

Journal of Forensic Sciences

The Journal of Forensic Sciences encourages authors to submit all previously unpublished reports and papers presented at the Academy’s annual meeting. Please submit your manuscripts electronically to http://mc.manuscriptcentral.com/jofs.

AAFS Abstract Policy

Presentations at AAFS annual meetings and corresponding abstracts must be formulated to promote education and to elevate accuracy, precision, and specificity in the forensic sciences. Presentations or abstracts that promote a commercial product, company, entity, or service will not be allowed at AAFS annual meetings. Presentations by commercial entities shall be limited to the science and not to an advertisement or promotion of their product over that of a competitor. Any abstract or presentation that is perceived by a Section Program Chair or the Academy Meeting Program Chair as a product endorsement will not be approved for presentation at the Meeting. A presentation given at a Meeting that, in the opinion of the Section Program Chair or the Academy Meeting Program Chair, is a product endorsement may result in the presenter and corresponding company being barred from making presentations at future AAFS meetings.
**INSTRUCTIONS FOR ABSTRACT SUBMISSION & LCD PROJECTION**

Presentations and abstracts will be allowed to mention a product by name only in the context of describing a scientific methodology or the source of sample. For example, specimens often have unique physical or chemical properties that are key to their identification or analysis (e.g., Dacron® fibers, Glock® rifling, 3M® tapes, explosive formulations, coating materials, etc.). It is appropriate for those materials to be specifically identified, since they are relevant to the scientific results, or references to specific reagents or instrumentation validated for use in the analytical procedure being presented where the use of a different product may affect the outcome of the analysis (e.g. Identifier™ Amplification Kit, Agilent® 5860 GC, HP-1 column, Olympus® BHP microscope, etc).

**General Instructions**

**Content of Abstract**

Abstracts should NOT be written in the first person.

Your abstract should be informative, containing:

1. A short specific title.
2. A sentence statement of how your presentation will impact the attendees.
3. A minimum of one-half page, single-spaced (approximately 400 words) to a maximum of one full page (approximately 700 words).
4. A general statement of conclusion, if possible.
5. A summary of the results obtained, if pertinent.
6. The Learning Objectives.
7. Three key words.
8. A brief synopsis of the content, or statement of the methods, whichever is pertinent.
9. A general statement of conclusion, if possible.

**Format of Abstract**

Your abstract must be typed and submitted in a legible format following the instructions provided below:

1. The title, names of authors with respective degree(s), and addresses must be stated exactly as you wish them to appear in the program. Indicate with an asterisk (*) who will be presenting.
2. Type abstract single spaced, 10-point type size, and return it along with a copy on disk.
3. Type all copy, including title, in upper and lower case; do not put in the header or footer of the document.
4. Attach one current electronic copy of presenting author’s curriculum vitae to original abstract form. Return the original abstract, with attached c.v., and a copy on disk, by August 1, to:
5. Proofread all information provided.
6. Follow instructions provided in typing abstract.
7. Attach one current electronic copy of presenting author’s curriculum vitae to original abstract form. Return the original abstract, with attached c.v., and a copy on disk, by August 1, to:

**Sample Abstract**

**Injury Pattern Analysis in Fatal Traffic Crash Investigation**

Michael D. Freeman, PhD, DC, MPH*, Oregon Health and Science University School of Medicine, Salem, OR 97302; and Clifford Nelson, MD, Medical Examiner Division, Oregon State Police, Portland, OR 97212-3092.

After attending this presentation, attendees will understand some principles of crash investigation, the necessary elements for the application of Injury Pattern Analysis, characteristic injury patterns of certain types of crashes, and an example of a practical application of Injury Pattern Analysis.

This presentation will impact the forensic science community by serving as a key aspect of fatal crash investigation as it can augment traditional means of investigation in a systematized format via interdisciplinary communication and collaboration.

Reconstruction of a fatal crash can be augmented, in certain circumstances, by information gleaned from the postmortem evaluation. Further improvement of the scope and accuracy of an investigation can result from evaluation of the injuries of crash survivors, taking into account the circumstances, by information gleaned from the postmortem evaluation.

The term “Injury Pattern Analysis (IPA)” is proposed as a description of a fatal crash investigation technique that utilizes accident investigation, and reconstruction techniques, occupant kinematics, postmortem records, hospital and healthcare provider acute injury records, and other evidence as an adjunct to the investigation of homicides resulting from fatal crashes.

This report will present a case study in IPA as an example of the practical application of the technique. It is recommended that medicolegal death investigators become familiar with the principles of IPA.
Complete All of the Following Information

NOTE: In order for your paper to be considered for presentation, you are required to complete ALL areas of this form. Incomplete information will be returned to the author for completion. To submit his/her abstract online, go to the AAFS website at: www.aafs.org.

1. Presentation Choice: □ Oral □ Poster □ Breakfast Seminar □ Luncheon

2. Section Selection: Please circle the session in which you desire to present a paper: Anthropology, Criminalistics, Digital & Multimedia Sciences, Engineering Sciences, General, Jurisprudence, Odontology, Pathology/Biology, Psychiatry & Behavioral Science, Questioned Documents, Toxicology, Last Word Society, YFSF Poster.

3. Amount of Time Required: __________________________

4. Presenting Author, Name, & Mailing Address: __________________________________________________________

   Presenting Author, Name, & Mailing Address: __________________________

   Telephone # (______) _____________________ Fax # (______) _____________________ Email ________________________________

5. Is the presenting author an AAFS member/affiliate or applicant? □ Yes □ No  If yes, AAFS ID # ________________________

   a. If AAFS member/affiliate/applicant, please list section affiliation: ____________________________________________

   b. Abstract should be considered for (check all that apply):

      Anthropology Ellis R. Kerley Award □ FSF Student Affiliate Scholarship □
      Anthropology J.L. Angel Student Award □ General Section Robert Gaffney Achievement Award □
      DMS* Outstanding Research Award □ Pathology/Biology Best Biology Trainee Award □ (publication-ready manuscript required)
      DMS* Outstanding Case Study Award □ Pathology/Biology Best Resident Paper □ (publication-ready manuscript required)
      FSF Emerging Forensic Scientist Award □ QD** Maureen Casey-Owens Best Paper/Poster □
      FSF Henry C. Lee Scholarship □ Toxicology Section Best Poster Award □
      *Digital & Multimedia Sciences
      **Questioned Documents

6. Co-Author(s) Name(s), Address(es), and Business Affiliation: (attach additional sheet if required) ______________________________________________________________

7. Has this paper been presented or published before? □ Yes □ No

   If yes, where and when? ____________________________________________________________________________

8. Audio/Visual Requirements: Each room will be equipped with a screen, electronic pointer, lectern microphone, and an LCD projector. All additional equipment must be requested and is subject to approval by the Section Chair.

   □ Other Equipment Requested: _______________________________________________________________________

9. AAFS Policy on Full Disclosure of Faculty Financial Interests or Relationships

   It is the policy of the Continuing Education Program of the American Academy of Forensic Sciences to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All faculty participating in these programs are expected to disclose to the program audiences: (1) any real or apparent conflict(s) of interest related to the content of their presentations, (2) discussion of unapproved (unlabeled) uses of pharmaceuticals/medical devices, and (3) ongoing research (preliminary) data. The intent of this disclosure is not to prevent a speaker with a financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments about the presentation. Additionally, disclosure for you and/or your spouse should include any relationships with entities that resell, distribute, and/or market health care products used on or by patients. It is also the policy of the AAFS that all speakers must disclose whether non-FDA approved uses of pharmaceutical products or medical devices are included in the presentation. In keeping with this procedure, the faculty or presenter is required to complete and sign the following disclosure statements:

   I. Will your presentation include any discussion of commercial products or services? □ Yes □ No

      If yes, please list all manufacturer(s) or provider(s) and describe the nature of the relationship(s) (attach additional pages as needed):

   II. Is this activity/presentation financially supported? □ Yes □ No  If yes, by whom? ____________________________ and in what form? □ Grant Support □ Paid Consultant □ Employee □ Shareholder □ Speakers Bureau

   III. Does this presentation include the discussion or use of unapproved (unlabeled) pharmaceuticals/medical devices and/or ongoing research? □ Yes □ No

      If yes, please describe (attach additional pages as needed):

      Disclosed information will be made available to participants in the Final Program provided to all registrants.

10. Complete the following:

   a. Representatives of the media are allowed to record my presentation. □ Yes □ No

   b. I hereby acknowledge that my abstract will be published in the AAFS Proceedings if accepted for presentation. (Please initial.) __________________________

   c. I acknowledge that I am required to comply with the AAFS guidelines for legible LCD projection and that structured abstracts are required. (Please initial.) __________________________

   d. I acknowledge that all authors contributing on this paper have been properly cited. I understand that only the authors listed on this form and in the online system will appear in the printed materials (e.g., Programs, Proceedings). (Please initial.) __________________________

   e. I acknowledge that any images to be presented will be accurate and will not misrepresent the outcome of treatment. (Please initial.) __________________________

   f. I hereby acknowledge that if the paper described by the abstract is accepted for presentation, AAFS will acquire a non-exclusive copyright of the abstract. (Please initial.) __________________________

   g. I understand that submission of this abstract is made with the commitment of the author(s) to present the paper at the AAFS Annual Meeting. Failure to present the paper without a valid excuse may result in its removal from the Proceedings, preclusion from future submissions, or both. (Please initial.) __________________________

   h. I acknowledge that all attending authors and co-authors on this submission/paper will be at least 18 years of age at the time of the meeting in February: (Please initial.) __________________________

I hereby acknowledge that I have read and comply with the requirements noted herein and that the information provided is true and correct.

__________________________  ____________________________
Signature  Date
COMPLETE FORM AND RETURN ORIGINAL, WITH ATTACHED C.V., ONE PHOTOCOPY, AND A COPY ON DISK BY AUGUST 1, 2019. If you wish to submit your abstract online, go to the AAFS website at: www.aafs.org.

- Type abstract, single spaced, 10-point size (or on attached separate page following format provided in Sample Abstract).
- **Do not type in all capital letters.** Type all copy, including title, author names, and addresses in upper and lower case; capitalize and punctuate exactly as you wish the abstract to appear.
- A single-spaced, full-page length document (minimum 400 to maximum 700 words) is required. Attach an additional sheet if required.

<table>
<thead>
<tr>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUTHORS</td>
</tr>
<tr>
<td>Name(s) and Address(es):</td>
</tr>
<tr>
<td>LEARNING OBJECTIVE and OUTCOME</td>
</tr>
<tr>
<td>Please state what the attendee can expect to learn, retain, or implement into his or her practice.</td>
</tr>
<tr>
<td>IMPACT STATEMENT</td>
</tr>
<tr>
<td>Please state how your presentation will impact the attendees in terms of: competence (ability), performance (competence put into “action”), or patient outcomes (if applicable).</td>
</tr>
</tbody>
</table>

| THREE KEY WORDS | TEXT |
Continuing medical, physician assistants, pharmacy, nursing, and optometry education (CME/CE) activities are conducted in the public interest; therefore, it is important to assure the public that education received by physicians and other health professionals through whom patient care decisions are made is conducted with the highest integrity, scientific objectivity, and in the absence of bias. A conflict of interest (COI) exists when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME/CE about the product or services of that commercial interest. As a Jointly Accredited provider, the Postgraduate Institute for Medicine is responsible for collecting information from its faculty, planners, and managers of CME/CE content and resolving those conflicts prior to the commencement of the CME/CE activity. The intent of the COI resolution process is to assure that provider, faculty, and planner financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of CME/CE activities for the profession.

**Criteria for Disclosure of Conflicts of Interest**
Faculty, planners, and managers who affect the content of a CME/CE activity are required to disclose their own financial relationships, as well as relationships to products or devices their spouse/life partner have, with commercial interests related to the content of this CME/CE activity of any amount over the past 12 months. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected (honoraria received from a CME/CE provider for serving as a CME/CE faculty member by you or your spouse/life partner, even though those funds may have been provided through an educational grant from a commercial interest, DO NOT HAVE TO BE DISCLOSED). A commercial interest is defined by the ACCME, AAPA, ACPE, ANCC, and ARBO/COPE as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relationships with governmental agencies (e.g., the NIH) do not have to be disclosed.

<table>
<thead>
<tr>
<th>Type of Financial Relationship</th>
<th>Indicate Applicable Manufacturer(s)/Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salary</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Royalty</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Receipt of Intellectual Property Rights/Patent Holder</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Consulting Fees (e.g., advisory boards)</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Contracted Research</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Ownership Interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Ownership Interest greater than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds)</td>
<td>☐ Self ☐ Spouse</td>
</tr>
<tr>
<td>Other</td>
<td>☐ Self ☐ Spouse</td>
</tr>
</tbody>
</table>

If you reported relationships in the chart above, will any of these relationships impact your ability to present an unbiased presentation?

- ☐ Yes ☐ No

- ☐ I have no real or apparent conflicts of interest to report.

- ☐ I agree to disclose any unlabeled/unapproved uses of drugs or products referenced in my presentation/materials.

NPI Number: ☐ I do not have an NPI Number.

---

1 For Royalty and Patent Holder relationships, include product name along with Manufacturer/Company. Product information will be used only to identify degree of conflict and will NOT be disclosed to the learners; there is no need to report rights and royalties if they are fully assigned to another party.

2 An accredited ACCME/ACPE/ANCC provider is NOT an agent for a manufacturer, whereas a company acting for a manufacturer in a promotional activity IS an agent.

3 Only include research funds received directly from industry; grants to your institution are reportable only when you’re the person or named investigator on the grant.